OncoMatch/Clinical Trials/NCT03537482
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Is NCT03537482 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies APG-2575 for hematologic malignancies.
Treatment: APG-2575 — This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic cell transplant
Lab requirements
Blood counts
Adequate bone marrow function independent of growth factor: ANC ≥1.0 X 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelets count ≥ 30 X 10^9/L (entry platelet count must be independent of transfusion within 7 days of first dose)
Kidney function
Adequate renal function as indicated by protocol
Liver function
Adequate liver function as indicated by protocol
Cardiac function
QTc interval ≤450ms in males, and ≤470ms in females
Adequate bone marrow function independent of growth factor: ANC ≥1.0 X 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelets count ≥ 30 X 10^9/L (entry platelet count must be independent of transfusion within 7 days of first dose). Adequate renal and liver function as indicated by protocol. QTc interval ≤450ms in males, and ≤470ms in females.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Jacksonville, Florida
- Duke Unviersity · Durham, North Carolina
- MDACC · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify